Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational
AssigneeArstat, Inc.
InventorArkady RUBIN
Life of this patent
Estimating the term…
Abstract
A method and intravaginal drug delivery device for reducing size of a uterine fibroid in a female in need thereof are provided. The method includes administering intravaginally to the female a therapeutically effective amount of an active agent, wherein the agent is delivered on a delivery device directly to uterine fibroid, wherein said amount is able to significantly reduce the size of the uterine fibroid, wherein the active agent is any one of selective progesterone receptor modulator (SPRM), an anti-progestin agent, and an anti-progestational agent.
Claims27
A method for reducing size of a uterine fibroid in a female in need thereof comprising:
- administering intravaginally to the female a therapeutically effective amount of an active agent, wherein the agent is delivered on a delivery device directly to uterine fibroid, wherein said amount is able to significantly reduce the size of the uterine fibroid, wherein the active agent is any one of selective progesterone receptor modulator (SPRM), an anti-progestin agent, and an anti-progestational agent.
An intravaginal drug delivery device comprising:
- a drug delivery device;
- a therapeutically effective amount of an active agent, wherein the drug delivery device delivers the active agent directly to uterine fibroids, the drug delivery device delivers a daily dose of the active agent which does not exceed 1.4 mg, wherein the active agent is any one of a selective progesterone receptor modulator (SPRM), an anti-progestin agent, and an anti-progestational agent.
Dependencies are inferred from the claim text.